HK1134240A1 - Leptomycin derivatives - Google Patents

Leptomycin derivatives

Info

Publication number
HK1134240A1
HK1134240A1 HK09111635.9A HK09111635A HK1134240A1 HK 1134240 A1 HK1134240 A1 HK 1134240A1 HK 09111635 A HK09111635 A HK 09111635A HK 1134240 A1 HK1134240 A1 HK 1134240A1
Authority
HK
Hong Kong
Prior art keywords
leptomycin derivatives
leptomycin
derivatives
Prior art date
Application number
HK09111635.9A
Other languages
English (en)
Inventor
Bouchard Herve
Commercon Alain
Ravi V J Chari
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37311892&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1134240(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1134240A1 publication Critical patent/HK1134240A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
HK09111635.9A 2006-06-09 2009-12-10 Leptomycin derivatives HK1134240A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06290948A EP1864682A1 (en) 2006-06-09 2006-06-09 Leptomycin derivatives
PCT/IB2007/001328 WO2007144709A2 (en) 2006-06-09 2007-05-23 Leptomycin derivatives

Publications (1)

Publication Number Publication Date
HK1134240A1 true HK1134240A1 (en) 2010-04-23

Family

ID=37311892

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09111635.9A HK1134240A1 (en) 2006-06-09 2009-12-10 Leptomycin derivatives

Country Status (29)

Country Link
US (2) US7816543B2 (es)
EP (3) EP1864682A1 (es)
JP (1) JP5162581B2 (es)
KR (1) KR20090018103A (es)
CN (2) CN101466409B (es)
AR (1) AR063668A1 (es)
AU (1) AU2007258896B2 (es)
BR (1) BRPI0712899A2 (es)
CA (1) CA2654322A1 (es)
CL (1) CL2007001648A1 (es)
CR (1) CR10459A (es)
EA (1) EA017345B1 (es)
EC (1) ECSP088936A (es)
GT (1) GT200800277A (es)
HK (1) HK1134240A1 (es)
HN (1) HN2008001788A (es)
IL (1) IL195419A0 (es)
MA (1) MA30689B1 (es)
ME (1) MEP88208A (es)
MX (1) MX2008015728A (es)
MY (1) MY148231A (es)
NO (1) NO20085127L (es)
NZ (1) NZ572947A (es)
SG (2) SG174067A1 (es)
TN (1) TNSN08463A1 (es)
TW (1) TWI411609B (es)
UA (1) UA95959C2 (es)
WO (1) WO2007144709A2 (es)
ZA (1) ZA200810015B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN101732308B (zh) * 2008-11-17 2011-11-30 中国人民解放军军事医学科学院毒物药物研究所 来普霉素b的新用途及含有它的药物组合物和产品
EP3100745B1 (en) 2009-02-05 2018-04-18 Immunogen, Inc. Novel benzodiazepine derivatives
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
UY32913A (es) 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
EP2533810B1 (en) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20 antibodies and uses thereof
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
MY183977A (en) 2011-02-15 2021-03-17 Immunogen Inc Cytotoxic benzodiazepine derivatives
PL2872157T3 (pl) 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US20150148411A1 (en) * 2013-11-25 2015-05-28 The Rockefeller University Compositions and methods for diagnosis and therapy of disorders related to alterations of myh9
JP6602834B2 (ja) 2014-06-30 2019-11-06 ターベダ セラピューティクス インコーポレイテッド 標的化コンジュゲートならびにその粒子及び製剤
MA43345A (fr) * 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017075495A1 (en) 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
US10402527B2 (en) 2017-01-04 2019-09-03 Stmicroelectronics S.R.L. Reconfigurable interconnect
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2019030284A1 (en) * 2017-08-09 2019-02-14 Helmholtz-Zentrum für Infektionsforschung GmbH NOVEL TARGETED CYTOTOXIC RATJADONE DERIVATIVES AND CONJUGATES THEREOF
US11531873B2 (en) 2020-06-23 2022-12-20 Stmicroelectronics S.R.L. Convolution acceleration with embedded vector decompression

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792522A (en) 1983-12-12 1988-12-20 Bristol-Myers Company Rigolettone antitumor complex
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4771070A (en) 1984-08-21 1988-09-13 Warner-Lambert Company CL-1957A antibiotic compound
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4764368A (en) 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
WO2001007013A2 (en) * 1999-07-22 2001-02-01 University Of Medicine And Dentistry Of New Jersey Thioamide moiety-containing polymer drug conjugates
US7238525B2 (en) 2000-06-30 2007-07-03 The Regents Of The University Of California Strategy for leukemia therapy
US20030091640A1 (en) * 2001-02-08 2003-05-15 Srinivasan Ramanathan Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents
EA010570B1 (ru) 2002-11-07 2008-10-30 Иммьюноджен, Инк. Антитело к cd33 и способы его применения
KR101200133B1 (ko) * 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
US7446196B2 (en) * 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
US7541330B2 (en) * 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
WO2006135371A1 (en) * 2005-06-09 2006-12-21 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives

Also Published As

Publication number Publication date
CN101466409B (zh) 2012-11-21
GT200800277A (es) 2009-06-16
CA2654322A1 (en) 2007-12-21
AU2007258896B2 (en) 2013-01-24
EA200870615A1 (ru) 2009-04-28
US20090182038A1 (en) 2009-07-16
MX2008015728A (es) 2009-01-09
MY148231A (en) 2013-03-29
JP2009539820A (ja) 2009-11-19
SG174066A1 (en) 2011-09-29
CL2007001648A1 (es) 2008-01-18
MA30689B1 (fr) 2009-09-01
EP2540320A1 (en) 2013-01-02
BRPI0712899A2 (pt) 2013-01-08
US7816543B2 (en) 2010-10-19
CR10459A (es) 2009-01-09
US20110002947A1 (en) 2011-01-06
AU2007258896A1 (en) 2007-12-21
TWI411609B (zh) 2013-10-11
AR063668A1 (es) 2009-02-11
UA95959C2 (en) 2011-09-26
HN2008001788A (es) 2012-08-27
WO2007144709A3 (en) 2008-06-12
EA017345B1 (ru) 2012-11-30
KR20090018103A (ko) 2009-02-19
JP5162581B2 (ja) 2013-03-13
SG174067A1 (en) 2011-09-29
IL195419A0 (en) 2009-08-03
EP2032172B1 (en) 2012-06-06
CN102731611A (zh) 2012-10-17
MEP88208A (en) 2011-12-20
TW200812996A (en) 2008-03-16
EP2032172A2 (en) 2009-03-11
TNSN08463A1 (en) 2010-04-14
WO2007144709A2 (en) 2007-12-21
ZA200810015B (en) 2010-02-24
ECSP088936A (es) 2009-01-30
NZ572947A (en) 2011-12-22
EP1864682A1 (en) 2007-12-12
NO20085127L (no) 2009-01-08
CN101466409A (zh) 2009-06-24

Similar Documents

Publication Publication Date Title
ZA200810015B (en) Leptomycin derivatives
ZA200807748B (en) Dihydropyrazolopyrimidinone derivatives
HK1134284A1 (en) Pyridizinone derivatives pyridizinone
IL193641A0 (en) Spiroindolinone derivatives
IL195013A0 (en) Pyridopyrimidinone derivatives
EP1973405A4 (en) HYDROXYALKYMARYLAMIDE DERIVATIVES
IL198319A0 (en) Spiroindolinone derivatives
EP2009005A4 (en) AZOLECARBOXAMIDE DERIVATIVE
IL195422A0 (en) 2-pyrazinecarboxamide derivatives
EP2098517A4 (en) NEW PHENYLISOXAZOLE-3-OLDERIVATE
IL192401A0 (en) Indol-3-yl-carbonyl-spiro-piperidine derivatives
IL198059A0 (en) 2-aminocarbonyl-pyridine derivatives
IL196364A0 (en) Aminoindazolylurea derivatives
HK1136276A1 (en) 5-hydroxymethyl-oxazolidin-2-one derivatives 5---2-
IL193211A0 (en) Indazole-heteroaryl derivatives
IL192799A0 (en) Substituted 4-phenylpiperidines
IL197152A0 (en) 5-phenyl-nicotinamide derivatives
EP2043633A4 (en) THIADIAZOLIDINONDERIVATE
IL197239A0 (en) Phenyloxyaniline derivatives
ZA200807460B (en) Spiroindolinone derivatives
EP2072498A4 (en) N-PHENYLOXAMIDE ACID DERIVATIVE
GB0614154D0 (en) Novel Pyriazine Derivatives
EP2128136A4 (en) DERIVATIVE OF 2-PHENYLNICOTINIC ACID
ZA200903280B (en) 2-aminocarbonyl-pyridine derivatives
GB0624214D0 (en) Benzotriazepinone derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170523